
ProteinQure Doses First Patient in Phase I Trial of PQ203 for Advanced Cancer
ProteinQure Marks Milestone with First Patient Dosed in Phase I Clinical Trial of PQ203, a Computationally Designed Peptide Therapy for Advanced Metastatic Cancers ProteinQure, a Toronto-based biotechnology company at the…












